|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
Acquired by a larger pharmaceutical company
|
|
gptkbp:business_model
|
research and development
|
|
gptkbp:ceo
|
gptkb:Dr._J._Michael_Bishop
|
|
gptkbp:clinical_expertise
|
has clinical expertise in oncology.
|
|
gptkbp:clinical_focus
|
gptkb:cancer_treatment
|
|
gptkbp:clinical_outcomes
|
aims to improve patient outcomes
|
|
gptkbp:clinical_partners
|
collaborates with hospitals
|
|
gptkbp:clinical_research
|
ongoing clinical studies
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
Phase 1 and Phase 2 trials
|
|
gptkbp:collaboration
|
Biopharmaceutical companies
|
|
gptkbp:collaborations
|
academic research institutions
works with scientists globally
|
|
gptkbp:community_engagement
|
engages with local communities
|
|
gptkbp:company_structure
|
gptkb:organization
|
|
gptkbp:drug_candidates
|
various drug candidates in development
|
|
gptkbp:drug_development
|
innovative drug candidates
|
|
gptkbp:drug_safety
|
focuses on drug safety
|
|
gptkbp:economic_development
|
aims for sustainable growth
|
|
gptkbp:financials
|
private equity funding
|
|
gptkbp:focus
|
cancer therapeutics
|
|
gptkbp:founded
|
gptkb:2007
|
|
gptkbp:founder
|
gptkb:Dr._J._Michael_Bishop
|
|
gptkbp:headquarters
|
gptkb:Malvern,_Pennsylvania
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tetra Logic Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:innovation
|
driven by innovation in drug development
|
|
gptkbp:instruction_set
|
multiple drug candidates
|
|
gptkbp:invention
|
multiple patents filed
|
|
gptkbp:investment
|
Venture capital firms
engagement with investors
|
|
gptkbp:investment_focus
|
oncology market
|
|
gptkbp:key_people
|
gptkb:Dr._J._Michael_Bishop
gptkb:David_A._Dyer
gptkb:Robert_J._Mc_Culloch
|
|
gptkbp:market
|
conducts market research
global pharmaceutical market
|
|
gptkbp:marketing_strategy
|
strategic partnerships
focused on niche markets
|
|
gptkbp:partnership
|
Various academic institutions
|
|
gptkbp:patient_access
|
improves patient access to therapies
|
|
gptkbp:product
|
TL32711
|
|
gptkbp:product_pipeline
|
cancer drugs
|
|
gptkbp:publication
|
peer-reviewed journals
|
|
gptkbp:regulatory_compliance
|
FDA approval process
complies with FDA regulations
|
|
gptkbp:research_areas
|
oncology
small molecule drugs
|
|
gptkbp:research_interest
|
significant R& D investment
|
|
gptkbp:team
|
experienced leadership team
|
|
gptkbp:technology
|
proprietary drug delivery systems
|
|
gptkbp:therapeutic_approach
|
targeted therapy
|
|
gptkbp:therapeutic_innovation
|
pioneers therapeutic innovations
|
|
gptkbp:type
|
gptkb:pharmaceuticals
|
|
gptkbp:type_of_business
|
operates in the US
|
|
gptkbp:website
|
www.tetralogic.com
|
|
gptkbp:bfsParent
|
gptkb:GSK
gptkb:Takeda
|
|
gptkbp:bfsLayer
|
4
|